Doris van Byssum
Psychiatric/Mental Health · Wheaton, ILNPI 1063515369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,110 of the $31,159 with a category attached, or 77.4%. Otsuka America Pharmaceutical, Inc. accounts for 86.0% of it on its own, with 22 other manufacturers making up the rest. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $159.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$27K
- Johnson & Johnson$782
- Janssen Scientific Affairs, LLC$681
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$521
- Alkermes, Inc.$396
- Lundbeck LLC$355
- plus $2K from 17 others
What the payments were for
- Consulting fees$5802%
- Speaking & faculty fees$24,11077%
- Travel & lodging$1,0833%
- Food & beverage$5,33917%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 64 | $26,794 |
| Johnson & Johnson(2 entities) | 19 | $782 |
| Janssen Scientific Affairs, LLC | 2 | $681 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $521 |
| Alkermes, Inc. | 9 | $396 |
| Lundbeck LLC | 27 | $355 |
| Corium, LLC | 12 | $343 |
| Axsome Therapeutics, Inc. | 5 | $196 |
| E.r. Squibb & Sons, L.L.C. | 3 | $170 |
| Idorsia Pharmaceuticals US Inc | 3 | $144 |
| Amgen | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| AbbVie | 5 | $97 |
| Tris Pharma Inc | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $58 |
| Almatica Pharma LLC | 3 | $58 |
| Merck | 3 | $53 |
| Bausch Health US, LLC | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$25,849
- INVEGA TRINZA$817
- LYBALVI$810
- INVEGA SUSTENNA$338
- CAPLYTA$227
- SPRAVATO$225
- COBENFY$125
- QUVIVIQ$122
- ABILIFY MAINTENA$121
- Auvelity$113
- Azstarys$102
How this compares
$31,159 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,336 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 52 | $2,438 |
| Lisdexamfetamine Dimesylate | 12 | $2,316 |
| Bupropion XlBupropion Hcl | 65 | $1,884 |
| Aripiprazole | 30 | $1,849 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,671 |
| Duloxetine Hcl | 34 | $1,546 |
| Clonazepam | 123 | $1,152 |
| Bupropion Hcl SrBupropion Hcl | 27 | $880 |
| Buspirone Hcl | 38 | $758 |
| Quetiapine Fumarate | 33 | $735 |
| Alprazolam | 91 | $710 |
| Clomipramine Hcl | 13 | $656 |
| Lamotrigine | 41 | $514 |
| Trazodone Hcl | 50 | $510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $108 | $4,33611 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $39653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Wheaton
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.